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Objectil·es. The aims of this study were to better characterize 
\'ah'e disease in systemic lupus erythematosus and to determine its 
association with antiphospholipid antibodies. 
Background. Estimates of the pre\'alence of \'ah'e disease in 
systemic lupus erythematosus ha\'e been higher in autopsy series 
than in clinical studies using transthoracic echocardiography. 
Antiphospholipid antibodies ha\'e been suggested to be a primary 
pathogenetic factor. 
Methods. Transesophageal echocardiography was performed 
on 1) 54 patients with lupus erythematosus, 22 of them with 
(group I) and 32 without (group II) anti phospholipid antibody; 
2) on 10 patients with antiphospholipid syndrome (group III); and 
3) on 35 normal subjects (group IV). 
Results. Patients in groups I and III had similar types and 
concentrations of antibodies. Leaflet thickening was found in 50% 
of group I, 47% of group II, 10% of group III and 9% of group 
IV patients (group I or II \'s. group III or IV, p < 0.03). Leaflet 
thickening in patients with lupus erythematosus was diffuse; it 
usually inmh'ed the mitral and aortic \'alws and was associated 
The valve disease associated with systemic lupus erythema-
tosus has been categorized as l) masses or vegetations 
(Libman-Sacks endocarditis), 2} leaflet thickening, 3) valve 
regurgitation and, infrequently, 4) valve stenosis (1,2). The 
true prevalence and distribution of types of lupus-associated 
valve disease are uncertain. The prevalence of valve abnor-
malities as assessed in prior transthoracic echocardiographic 
studies (1-5) ranges from 0% to 79%. Because of limitations 
in the image quality of these studies, these estimates may be 
low. Postmortem studies (6-9) generally yield higher esti-
mates (range 13% to 100%). 
Transesophageal Doppler echocardiography produces 
high resolution images of the cardiac valves and is superior 
to transthoracic echocardiography in the detection of valve 
abnormalities (10,11). Therefore, it should yield more accu-
rate Information about the true prevalence and type of valve 
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with \'alve regurgitation (73%) or \'al\'e masses (50%). Valve 
masses were obserwd in 41 % of group I, 25% of group II, 10% of 
group III and in none of group IV patients (group I or II \'s. group 
IV, p < 0.002). Most \'alw masses in patients with lupus erythe-
matosus were located near the base on the atrial side of the mitral 
\'ah'e or on the wssel side of the aortic \'alw, had variable size (0.2 
to 0.85 cm2), shape and echodensity. Valve regurgitation was 
obsen'ed in 64% of group I, 59% of group II, 10% of group III 
and 20% of group IV patients (group I or II \'s. group III or IV, 
p < 0.006). Moderate or se\'ere regurgitant lesions were noted in 
27% of group I and 25% of group II patients. 
Conclusions. Lupus erythematosus val\'e disease is frequent 
(74 %) regardless of the presence or absence of antiphospholipid 
antibodies. Therefore anti phospholipid antibodies may not be a 
primary pathogenetic factor. The characteristic appearance of 
leaflet thickening and masses in patients with lupus erythematosus 
may be unique. 
(J Am Coll CardioI1992j20:1127-34) 
abnormalities in patients with lupus erythematosus than that 
obtained with previously utilized methods. 
The pathogenesis of lupus-associated valve disease is 
unknown. Recent reports (4,12,13) suggest that the antiphos-
pholipid antibodies, which include anticardiolipin antibod-
ies, lupus anticoagulant antibody and false positive Venereal 
Disease Research Laboratory (VDRL) test may cause valve 
injury. These antibodies are IgG, IgM or IgA immunoglob-
ulins directed against negatively charged phospholipids 
present in the membrane of endothelial cells. They have 
been found in patients with lupus erythematosus, patients 
with the anti phospholipid syndrome and infrequently in 
normal subjects (14,15). Patients with antiphospholipid syn-
drome are those with positive anti phospholipid antibodies 
and arterial or venous thrombotic events, thrombocytopenia 
or frequent miscarriages who do not meet criteria for sys-
temic lupus erythematosus. Valve abnormalities similar to 
those associated with lupus erythematosus have been de-
scribed in this syndrome (4,16,17). 
The purpose of this study is twofold: l) to better charac-
terize the valve abnormalities in patients with systemic lupus 
erythematosus by using transesophageal echocardiography, 
and 2) to determine whether there is a specific association 
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between antiphospholipid antibodies and lupus-associated 
valve disease. 
Methods 
Study patients. This research protocol was approved by 
the Human Research Committee of the University of New 
Mexico and all subjects signed informed consent. The study 
group consisted of 54 patients with systemic lupus erythe-
matosus, 10 patients with antiphospholipid syndrome and 35 
age- and gender-matched normal subjects. The diagnosis of 
systemic lupus erythematosus was made according to the 
criteria of the American Rheumatologic Association (l8). 
The patients with this diagnosis were unselected, represent-
ing about 80% of outpatients <60 years of age followed up at 
the Rheumatology-Immunology Division at two affiliated 
hospitals. Twenty-one patients with lupus erythematosus 
>60 years of age were excluded on the basis of age because 
degenerative valve thickening, calcification and regurgita-
tion are frequent in this age group (19,20). We also excluded 
three other patients with lupus erythematosus: two patients 
who had a history of rheumatic fever and one patient who 
was an intravenous drug abuser. 
The diagnosis of antiphospholipid syndrome was based 
on the presence of one or more antiphospholipid antibodies 
and I} evidence of the associated clinical syndrome of 
arterial or venous thrombosis, or 2} a history of miscarriages 
but no criteria for systemic lupus erythematosus, or 3} both. 
Four of these patients were defined as having primary 
antiphospholipid syndrome and six patients as having a 
secondary syndrome. These patients also were unselected 
and represented 10 of 13 patients diagnosed with this condi-
tion over the last 5 years by the rheumatology and hematol-
ogy-oncology divisions. All study subjects underwent rheu-
matologic and serologic testing to confirm diagnoses. All 
subjects studied were outpatients in stable condition. Four 
patients (7%) with lupus erythematosus had a history of a 
heart murmur. The normal subjects had no evidence of 
medical illness by history or physical examination and had 
negative antiphospholipid antibodies. 
Antiphospholipid antibody profile. Serum for determina-
tion of anticardiolipin antibodies (IgG and IgM) was drawn in 
all subjects including the control group at the time of 
transesophageal Doppler echocardiography. The anticardio-
lipin antibodies were measured in a reference laboratory by 
an enzyme-linked immunosorbent assay (ELISA) and ex-
pressed in IU defined by standard sera (21). The IgG and 
IgM anticardiolipin antibodies were considered present 
when >8 and> 10 IU, respectively, were detected. 
Patients tested positive with lupus anticoagulant antibody 
or false positive VDRL were included in the groups with 
antiphospholipid antibody. 
Doppler echocardiography. All subjects underwent 
monoplane or biplane transesophageal color Doppler echo-
cardiography with use of a Hewlett-Packard 77020 AiAC/AR 
with a 5 MHz transducer. Echocardiographic studies were 
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copied in random order and interpreted by an experienced 
observer unaware of all clinical data. In addition to standard-
ized transesophageal echocardiographic views (l0), careful 
scanning of the mitral and aortic valves was performed in 
mUltiple planes to define anatomy and the presence and 
severity of valve regurgitation or stenosis, or both. 
To assess mitral leaflet thickness, M-mode echocardio-
grams were recorded at the leaflet base, mid and tip in the 
four-chamber view during systole. Similar M-mode record-
ings were made of the noncoronary cusps and right coronary 
cusp of the aortic valve in the long-axis view. M-mode 
echocardiograms of the left and right coronary cusps also 
were obtained in the short-axis view. Imaging of the tricus-
pid valve was performed in a manner analogous to that of the 
mitral valve. The pulmonary valve was not included in the 
present study because of its limited and variable visualiza-
tion by transesophageal echocardiography. 
Left ventricular size, wall motion and function and the 
appearance of the pericardium were assessed. 
Criteria for echocardiographic interpretation. Valve ab-
normalities were classified into three principal categories: 
thickening of leaflets with or without calcification, valve 
masses and valve regurgitation or stenosis, or both. 
Valve thickening. Mitral leaflet thickness on transesoph-
ageal two-dimensional echocardiographic images was mea-
sured in 10 randomly selected control subjects and found to 
be 1 ± 1 mm at the base and midportions, and 2 ± 1 mm at 
the tip. Aortic cusp thickness in the same control subjects 
was found to be I ± 1 mm. Abnormal leaflet thickening was 
considered present when at least two leaflets showed a 
thickness ;:::3 mm (for the mitral valve) and >2 mm (for the 
aortic valve) or when noted in one leaflet if an associated 
mass or regurgitation of the respective valve, or both, was 
noted. Calcification associated with thickening was consid-
ered present when acoustic shadowing was demonstrated 
from a region of high reflectance. 
Valve masses. A mass was defined as an abnormal 
localized echodensity,with well defined borders either as 
part of or adjacent to valve leaflets, the subvalvular appara-
tus, great vessels or on the atrial or ventricular walls. The 
size of the mass on the two-dimensional image was deter-
mined by planimetry and expressed in cm2• 
Regurgitation. Grading of regurgitation severity was 
based on the size and duration of the Doppler color flow jet. 
Regurgitation was trivial if the jet extended into the receiving 
chamber for <1 cm and lasted <100 ms. It was mild if the jet 
extended only 1 to 2 cm and persisted throughout the 
regurgitant period. It was moderate if the jet was >2 cm and 
occupied up to 50% of the atrial or left ventricular outflow 
tract area (for mitral and aortic regurgitation), or if the 
halftime was <400 ms (for aortic regurgitation). It was 
severe ifthejet was >2 cm and occupied >75% of atrial or 
left ventricular outflow tract area or if halftime was <200 ms 
(for aortic regurgitation). Trivial lesions were considered 
absent for the purpose of analysis. 
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Mean ± SD 
Range 
Disease duration (yr) 
Mean ± SD 
Range 
Group I 
(SLE + AB) 
22 
21; 95 
37 ± 13 
16 to 57 
9.3 ± 9.3 
0.2 to 30 
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Group II Group III Group IV 
(SLE - AB) (APS) (normal) 
32 IO 35 
28;88 4;40 27; 77 
40 ± IO 42 ± IO 36 ± IO 
21 to 58 30 to 58 17 to 57 
9.0 ± 7.3 3.3 ± 2.1 
1.0 to 35 1.0 to 6.0 
'Groups I, II and IV vs. group III, p < 0.02. AB = anti phospholipid antibody; APS = anti phospholipid 
syndrome; SLE = systemic lupus erythematosus. 
Statistical analysis. The frequency of each type of valve 
abnormality was compared between groups by the chi-
square test. The two sample t test (for two groups) and 
analysis of variance (for more than two groups) were used to 
compare the means of continuous variables. A p value < 
0.05 was considered significant. 
Results 
Study group. The study patients were classified into four 
groups by clinical diagnoses (Table I). Groups differed only 
by predominance offemale gender in group I, II or IV versus 
group III (p < 0.02). 
Antibody profile. The patient groups with antibodies 
(groups I and III) showed a similar frequency of anticardio-
lip in and lupus anticoagulant antibodies. False positive 
VDRL was more frequent in group I (p < 0.03) (Table 2). 
Most patients with one type of antibody had other anti-
body types detected. All patients with lupus anticoagulant 
antibodies had at least one additional antibody type present. 
Groups I and III had a similar mean concentration of the IgG 
and IgM anticardiolipin antibodies (Table 3). 
Valve abnormalities on transesophageal echocardiography. 
The frequency of valve abnormalities in groups I to IV is 
presented in Table 4. Valve abnormalities of at least one type 
were very common in patients with lupus erythematosus 
(74%) regardless of the presence or absence of antiphospho-
Table 2. Frequency and Distribution of Antiphospholipid 
Antibodies in Groups I (SLE + AB) and III (APS) 
Group I 
(SLE + AB) Group III (APS) 
Antibody Type No. % No. % 
Anticardiolipin 
IgG 17 77 9 90 
IgM 9 41 3 30 
Lupus anticoagulant 6 27 4 40 
False positive VDRL' 13 59 2 20 
'Group I vs. group III, p < 0.03. VDRL = Veneral Disease Research 
Laboratory test; other abbreviations as in Table I. 
lipid antibodies. More than one valve abnormality was 
present in 50% of patients in group I and in 38% of patients 
in group II. Patients in these two group had a significantly 
higher frequency of valve abnormalities than did those in 
group III or IV, (group I or II vs. group III or IV, p < 0.02; 
group I vs. group II or III vs. group IV, p = NS). 
Valye thickening. Valve leaflet thickening was a common 
finding in patients with lupus erythematosus regardless of 
the presence (II [50%] of 22) or absence (15 [47%] of 32) of 
anti phospholipid antibodies. In contrast, this abnormality 
was uncommon in patients with the anti phospholipid syn-
drome (I [10%] of 10) or in normal subjects (3 [9%] of 35) 
(group I or II vs. group III or IV, p < 0.03; group I vs. group 
II or III vs. group IV, p = NS). 
In group I, nine patients had mitral, seven had aortic and 
one had mitral chordal thickening. In group II, II patients 
had mitral, 9 had aortic, 2 had mitral chordal and I had 
tricuspid valve thickening. In both groups, the anterior and 
posterior leaflets of the mitral valve and each of the three 
aortic valve cusps were similarly affected. Diffuse leaflet 
thickening (aortic in 9, mitral in 12) was observed in 20 
patients with lupus erythematosus (Fig. I and 2). Localized 
thickening (aortic in 8, mitral in 7) was seen in 13 patients 
with lupus erythematosus and was limited to the leaflet base 
in six valves, mid and tip portion in five valves and to the tip 
in four valves (Fig. 3). Most patients with lupus erythema-
tosus (70%) had more than one leaflet and nine patients 
(35%) had more than one valve affected. Nineteen patients 
with lupus erythematosus (73%) with valve thickening had 
associated valve regurgitation, 13 (50%) had a mass and 12 
(46%) had both. The extent and location of valve thickening 
Table 3. Concentration of IgG or IgM Anticardiolipin Antibodies 
in Groups I and III 
Group I Group III 
Antibody (SLE + AB) (APS) 
IgG (IU) 59 ± 61 65 ± 35 
IgM (lU) 34 ± 24 40 ± 22 
All values are expressed as mean value ± 1 SD. Abbreviations as in 
Table I. 
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Table 4. Frequency of Valve Abnormalities on Transesophageal Echocardiography 
Group Group II Group III Group IV 
(SLE + AB) (SLE - AB) (APS) (normal) 
No. % No. % No. % No. % 
Total patients 22 32 10 35 
Valve abnormalities 
Regurgitation 14 64 19 59 10 1 20 
Thickening II 50 15 47 10 3 9 
Masses 9 41 8 25 10 0 
Any abnormality 17 77 23 72 3 30 8 23 
Group I vs. group II or III vs. group IV, p = NS for all abnormalities; group I or II vs. group Ill, p < 0.03 for 
regurgitation, thickening or any abnormality; group I or II vs. group IV, p < 0.002 for all abnormalities. 
Abbreviations as in Table l. 
were similar in groups I and II. Only three patients (12%) 
with leaflet thickening had associated calcification. Mitra! 
anulus thickening or calcification was not noted. 
Valve masses. Seventeen (31 %) of all patients with lupus 
erythematosus had a valve mass, nine (41%) in group I and 
eight (25%) in group II. Only one patient in group III had a 
valve mass (group I vs. group III, p < 0.08; group I or II vs. 
group IV, p < 0.002). In group I, 12 masses were seen: 7 on 
the aortic valve, 3 on the mitral valve and 2 on the mitral 
chordae. In group II, masses were detected: 5 on the 
aortic valve, 3 on the mitral valve, 2 on the mitral chordae 
Figure 1. Diffuse thickening of the three aortic valve cusps in a 
patient with systemic lupus erythematosus with antiphosphoiipid 
antibody. This patient had severe aortic regurgitation. LA = left 
atrium; lee = left coronary cusp; nee = noncoronary cusp; rcc = 
right coronary cusp; RV == right ventricle. 
and 1 on the tricuspid valve. In both groups, the valve 
masses were equally distributed among the valve leaflets. 
Two thirds (12 of 18) of aortic and mitral valve masses 
were located on the basal portion of the leaflets, and one 
third were located on the mid and distal leaflets. Five of six 
mitral valve masses were located on the atrial side of the 
valve (Fig. 2 and 3). Eight of 12 aortic valve masses were on 
the aortic vessel side (Fig. 4 and 5). Most patients (71%) with 
lupus erythematosus who had valve mass had associated 
thickening of the respective valve leaflets and 88% had 
associated thickening or regurgitation of the respective 
valve. No masses were seen on the aortic, ventricular or 
atrial walls. 
Valve masses were of variable size (0.2 to 0.85 cm2) and 
Figure 2. Diffuse mitral valve thickening and a posterior mitral 
leaflet mass (arrow) in a patient with systemic lupus erythematosus 
with negative antiphospholipid antibody. There was associated mild 
mitral regurgitation. ami = anterior mitral leaflet; LA = left atrium; 
LV = left ventricle; pml = posterior mitral leaflet. 
lACC Vol. 20, No.5 
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Figure 3. Mitral valve thickening and a mass in a patient with 
systemic lupus erythematosus with anti phospholipid antibody. This 
transesophageal four-chamber view shows thickening of the mid and 
tip portions of the anterior (amI) and posterior (pm!) mitral leaflets. 
There is an irregular mass (arrow) on the atrial side of the posterior 
mitral valve leaflet. Moderate mitral regurgitation was present. 
Abbreviations as in Figures I and 2. 
shape, had irregular borders and heterogeneous echodensity 
and had no independent motion (Fig. 2 to 5). 
Valve regurgitation. Valve regurgitation was a frequent 
abnormality (61%) in patients with lupus erythematosus. 
Fourteen (42%) of all patients with lupus erythematosus-
associated valve regurgitation had moderate or severe regur-
gitant lesions. Three patients with lupus erythematosus-
associated severe mitral or aortic regurgitation had 
Figure 4. Aortic valve mass in a patient with systemic lupus 
erythematosus with negative antiphospholipid antibody. This trans-
esophageal longitudinal view shows a mass (arrow) of irregular 
borders and irregular echogenicity located at the base of the 
noncoronary cusp (nee) and anteromedial aortic root wall. No aortic 
regurgitation was detected. Abbreviations as in Figures and 2. 
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Figure 5. Aortic cusp mass lesions in a patiem with systemic lupus 
erythematosus with negative antiphospholipid antibody. This trans-
esophageal longitudinal view of the left ventricular (LV) outflow 
tract shows a small mass (arrow) on the coronary cusp (rcc) 
and another mass (arrowhead) at the base the noncoronary cusp 
(nee). No aortic regurgitation was detected. RA = right atrium; 
other abbreviations as in Figure 1. 
respective mild mitral or aortic stenosis. The frequency and 
severity of regurgitation in each valve was similar in patients 
with lupus erythematosus with or without antibody (Table 
5). Patients in group 1 or II had significantly more frequent 
and more severe lesions compared with patients in group III 
or IV (p < 0.005). In group I 27% and in group II 25% of all 
patients had moderate or severe lesions, and an equal 
number of patients in each group had more than one regur-
gitant valve. No patient in group III or IV had more than 
single or mild lesions. 
Other cardiac findings. Eleven patients with lupus 
erythematosus (20%) (six in group I and five in group II) had 
segmental or global left ventricular systolic dysfunction. In 3 
of the 11, severe left ventricular systolic dysfunction was 
associated with severe valve disease; the other 8 had left 
ventricular dysfunction without significant valve disease. 
Four of the II patients underwent coronary angiography, 
and 3 of the 4 were found to have coronary artery disease. 
One patient had a sinus of Val salva aneurysm associated 
with severe aortic regurgitation and mild aortic stenosis. 
Only two patients had pericardial effusion. 
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Table 5. Valve Regurgitation Distribution and Severity in Groups I (SLE + AB) and II (SLE - AB) 
Mitral Regurgitation Aortic Regurgitation Tricuspid Regurgitation 
Group I Group II Group I 
No. % No. % No. 
Mild 7 64 10 67 
Moderate 3 27 4 27 0 
Severe 9 I 7 2 
Total 11 15 3 
Abbreviations as in Table 1. 
Discussion 
Major findings. There are four major findings in this 
study. 1) Valve disease is present in the majority of patients 
with systemic lupus erythematosus. 2) Patients with lupus 
erythematosus have a similar frequency and severity of 
valve disease regardless of the presence or absence of 
antiphospholipid antibodies. 3) Antiphospholipid antibodies 
in the absence of lupus erythematosus were not associated 
with valve disease. 4) The leaflet thickening and associated 
masses observed by transesophageal echocardiography in 
patients with lupus erythematosus have an appearance that 
may be unique to this disease. 
Comparison with previous studies. The results of this 
study differ from those of recent studies. We observed a 
relative lack of valve disease in patients with the primary or 
secondary antiphospholipid syndrome (10%). Nihoyannop-
oulos et al. (4) reported a much higher incidence (67%) of 
valve disease in patients with either syndrome and Brenner 
et al. (22) reported valve abnormalities in 32% of patients 
with the primary anti phospholipid syndrome. These differ-
ences may be related to the small size of the groups studied 
in combination with other selection factors. Our subjects 
were neither suspected of having heart disease nor referred 
for echocardiography. A difference in valve disease preva-
lence in the primary and secondary syndromes may warrant 
consideration. In our study, an equal number of patients 
with anti phospholipid syndrome had a primary or a second-
ary syndrome. The duration of the disease also may influ-
ence the frequency of valve disease. 
The reported prevalence of lupus erythematosus-
associated valve disease varies widely depending on the 
study methods used and patients studied. Bahl et al. (5) 
recently reported the virtual absence of valve disease in 
patients with a diagnosis of lupus erythematosus of < 1 
year's duration. Galve et al. (I) reported an 18% prevalence 
of abnormal valve morphology in patients with chronic lupus 
erythematosus. Nihoyannopoulos et al. (4) found an overall 
28% prevalence of valve disease (40% in those with anticar-
diolipin antibodies and 14% in those without antibodies) in 
patients with lupus erythematosus. Enomoto et al. (3) re-
ported a 79% prevalence of valve regurgitation in patients 
with lupus erythematosus. Pathologic studies generally yield 
an estimate of> 50% for the prevalence of val ve involvement 
Group II Group I Group II 
% No. % No. % No. % 
33 3 60 7 100 6 60 
20 0 4 40 
66 I 20 0 0 
5 7 10 
in patients with lupus erythematosus. By contrast, the 
present data showed a prevalence of 77% in patients with 
lupus erythematosus with antibodies and of 72% in those 
without antibodies. 
Several factors probably contribute to the variable results 
of available studies. It is likely that transthoracic echocar-
diographic studies underestimate the true prevalence. Also, 
studies of patients older than 60 years may overestimate the 
presence of valve disease because of degenerative disease. 
In addition, studies including patients referred for suspected 
valve disease or with more severe lupus erythematosus may 
overestimate the frequency of valve disease. 
The mean duration of lupus erythematosus in this study 
of 9.2 ± 8.4 years (range 0.2 to 35) may have contributed to 
the high prevalence of valve disease. However, overestima-
tion of valve disease probablY was reduced by excluding 
subjects over age 60 years. Our subjects were not referred 
because of suspected valve disease (only 4 of 54 were aware 
of having a heart murmur) or because of severe lupus 
erythematosus. The prevalence of lupus-associated valve 
disease in this study is generally representative of an outpa-
tient population, although skewing of our study group 
toward more severe lupus erythematosus cannot be ex-
cluded. 
Pathogenesis of systemic lupus· associated valve disease. 
Our results do not support the hypothesis that antiphospho· 
lipid antibodies are a key pathogenic factor for valve disease 
in patients with lupus erythematosus (4). Neither the pres-
ence nor the concentration of IgG or IgM anticardiolipin 
antibodies, nor the presence of lupus anticoagulant antibody 
nor a false positive VDRL was associated with more fre-
quent or more severe valve disease .. In addition, careful 
review of our data failed to show any difference in the 
appearance of leaflet thickening or associated masses be-
tween patients with lupus erythematosus with or without 
antibodies. 
These data suggest caution in attributing valve disease to 
the simple presence of anti phospholipid antibodies. The 
participation of such antibodies in this process is possible, 
but their presence does not seem to be required, and these 
data suggest that other factors may be important as well. 
Comparison with rheumatic valve disease. Important dif-
ferences were found in this study between the valve abnor· 
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malities of lupus erythematosus-associated valve disease 
and those of rheumatic valve disease. In patients with lupus 
erythematosus, valve leaflet thickening was generally diffuse 
rather than localized to the leaflet tips, as is typical for 
rheumatic disease. When localized leaflet thickening was 
noted in patients with lupus erythematosus, the leaflet mid-
portion or base was usually involved. Only minimal involve-
ment of the mitral subvalvular apparatus was observed in 
our patients with lupus erythematosus. This involvement 
took the form of small masses attached to normal-appearing 
chordae, without the chordal thickening, fusion and calcifi-
cation characteristic of rheumatic disease. Valve masses in 
lupus erythematosus were frequently located near the base 
of leaflets, and calcification was not a prominent feature. In 
contrast, mass lesions associated with rheumatic disease are 
usually located near leaflet tips and are heavily calcified. In 
both diseases the aortic and mitral valves tend to be in-
volved, and regurgitation usually predominates although 
stenosis has been reported (23,24). Regurgitant lesions were 
the rule in our study as in several others (3,12,28). 
Comparison with postmortem studies of lupus-associated 
valve disease. The findings of this study differ from those of 
the early pathologic studies of lupus-associated valve dis-
ease by Libman and Sacks (6), Klemperer (7) and Brigden 
(8). These investigators described frequent tricuspid involve-
ment that was not confirmed by more recent pathologic and 
echocardiographic studies or in our study (1-4,25,26). They 
also observed aortic valve masses primarily on the ventric-
ular side of the valve, whereas we observed these lesions 
usually on the vessel side. Similarly, they reported mitral 
lesions to be near the leaflet tips on either the ventricular or 
the atrial surface, whereas the mitral masses in our study 
were primarily at the leaflet base on the atrial surface. 
Finally, we did not observe the endocardial ("pocket") 
lesions previously reported by these investigators. 
Some of these differences may be related to certain 
limitations of trans esophageal echocardiography. The mono-
plane transesophageal technique allows only a limited num-
ber of imaging planes for the detection of ventricular en-
docardial lesions or abnormalities of the tricuspid valve. 
Nevertheless, we think that the differences between the 
early and recent studies may reflect the effects of current 
therapy for lupus erythematosus on the development of 
valve disease. 
Lupus-associated valve disease versus infective endocardi-
tis. Lupus-associated valve masses differ from infection-
associated masses by their location, appearance and mobil-
ity. Lupus-associated valve masses are predominantly 
located near the leaflet base, whereas infection-associated 
masses are almost always located at the leaflet's line of 
closure. Lupus-associated valve masses are of heteroge-
neous echodensity and usually show central regions with 
high reflectance suggesting connective tissue or even calcific 
density; vegetations caused by acute infective endocarditis 
usually demonstrate a homogeneous soft tissue density. As 
observed by transesophageal echocardiography, the lupus-
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associated valve masses move exactly parallel to the motion 
of the related leaflet, whereas infection-associated vegeta-
tions show vibratory or rotatory motion at least partly 
independent from the motion of the valve. 
Limitations of the study. The small number of patients in 
our study with antiphospholipid syndrome may cause error 
in estimation of the prevalence of valve disease in these 
patients. Similarly, the small number of patients with an-
tiphospholipid syndrome in other series limits the validity of 
the reported association between valve disease and antibod-
ies. Conversely, the large number of our patients with lupus 
erythematosus with and without antibodies makes a strong 
association between antiphospholipid antibodies and valve 
disease unlikely, although we do not have the statistical 
power to rule out an association. 
The lack of pathologic confirmation of transesophageal 
echocardiographic findings in our study limits the assess-
ment of the accuracy of this technique. Systemic lupus 
erythematosus is a complex and protean disease, and factors 
such as the duration of active disease, the status of other 
immunologic markers and the duration of steroid, cytotoxic 
or antithrombotic drug therapy all may have a major impact 
on the development of valve disease. The relation of these 
important factors to either valve disease or antiphospholipid 
antibodies was not analyzed in this study. In addition, 
longitudinal, controlled studies would be useful to fully 
define the role of antiphospholipid antibodies in lupus-
associated valve disease. It is possible that antiphospholipid 
antibodies over a long time or at high concentrations, or 
both, contribute to valve involvement in this disease. 
Clinical implications oflupus-associated valve disease. The 
discovery of valve disease in a patient with lupus erythema-
tosus has several important implications. The most feared 
consequence of valve involvement is progression to severe 
valve dysfunction and the need for valve replacement 
(27,28). Two patients in our study underwent aortic valve 
replacement because of symptomatic severe aortic regurgi-
tation. However, lupus-associated valve disease may 
present with other important clinical sequelae before signs or 
symptoms of severe valve dysfunction develop. For exam-
ple, valve lesions may serve as a substrate for systemic 
thromboembolism (29,30). Six patients in our study with 
valve disease had previously documented transient ischemic 
attacks or strokes. Although the etiologic role of the valve 
abnormalities is not proved in these patients, valve involve-
ment was not suspected in any of these patients before the 
neurologic event occurred. The additional valve data obtain-
able by transesophageal echocardiography suggests that this 
diagnostic study may be indicated in patients with systemic 
lupus erythematosus with transient or permanent focal cere-
brovascular dysfunction to detect a valvular or other cardiac 
substrate for thromboembolism. Infective endocarditis is 
another potential complication that has been reported clini-
cally and pathologically (26,30,31). Finally, valve disease 
may be an important indicator of the degree of activity or 
severity, or both, of systemic lupus erythematosus. 
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Conclusions. This study has shown with transesophageal 
echocardiography that patients with systemic lupus erythe-
matosus have a similar prevalence and severity of valve 
disease whether or not they have antiphospholipid antibod-
ies. These data do not support the hypothesis that antiphos-
pholipid antibodies are a primary pathogenetic factor in 
lupus-associated valve disease. Finally, the characteristic 
appearance of leaflet thickening and associated masses may 
be unique to lupus-associated valve disease. 
We gratefully thank Dorothy Pattack, PhD for her expert statistical contribu-
tion. 
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